- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 2 - Genetics and Next-Generation Sequencing
Dr Kumar continues his analysis of the genetic and familial probability of a patient being diagnosed with multiple myeloma.
Dr Kumar continues his analysis of the genetic and familial probability of a patient being diagnosed with multiple myeloma.
Dr Chernew questions the value of circulating plasma cells as independent prognostic markers in newly diagnosed multiple myeloma, as well as circulating serum microRNAs for diagnosis of multiple myeloma.
The panelists then discuss next-generation sequencing, deep sequencing, and ASO-qPCR in detecting minimal residual disease (MRD). Dr Kumar says there is a growing interest in MRD and explains all the emerging developments for detection of MRD.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
